## Dorota Åażewska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1655202/publications.pdf Version: 2024-02-01



DODOTA ÅAÅ1/ FUNSKA

#	Article	IF	CITATIONS
1	The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism. Scientific Reports, 2018, 8, 13077.	3.3	58
2	Anticonvulsant and procognitive properties of the non-imidazole histamine H3 receptor antagonist DL77 in male adult rats. Neuropharmacology, 2016, 106, 46-55.	4.1	57
3	Recent advances in histamine H <sub>3</sub> receptor antagonists/inverse agonists. Expert Opinion on Therapeutic Patents, 2010, 20, 1147-1169.	5.0	51
4	Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands. European Journal of Medicinal Chemistry, 2014, 83, 534-546.	5.5	46
5	The dual-active histamine H3 receptor antagonist and acetylcholine esterase inhibitor E100 ameliorates stereotyped repetitive behavior and neuroinflammmation in sodium valproate induced autism in mice. Chemico-Biological Interactions, 2019, 312, 108775.	4.0	44
6	New developments around histamine H <sub>3</sub> receptor antagonists/inverse agonists: a patent review (2010 – present). Expert Opinion on Therapeutic Patents, 2014, 24, 89-111.	5.0	40
7	Antinociceptive effects of novel histamine H <sub>3</sub> and H <sub>4</sub> receptor antagonists and their influence on morphine analgesia of neuropathic pain in the mouse. British Journal of Pharmacology, 2018, 175, 2897-2910.	5.4	36
8	Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonists. Bioorganic and Medicinal Chemistry, 2006, 14, 3522-3529.	3.0	35
9	The computer-aided discovery of novel family of the 5-HT6 serotonin receptor ligands among derivatives of 4-benzyl-1,3,5-triazine. European Journal of Medicinal Chemistry, 2017, 135, 117-124.	5.5	33
10	Anticonvulsive effect of nonimidazole histamine H3 receptor antagonists. Behavioural Pharmacology, 2014, 25, 245-252.	1.7	31
11	Chlorophenoxy aminoalkyl derivatives as histamine H3R ligands and antiseizure agents. Bioorganic and Medicinal Chemistry, 2016, 24, 53-72.	3.0	28
12	The Histamine H3 Receptor Antagonist E159 Reverses Memory Deficits Induced by Dizocilpine in Passive Avoidance and Novel Object Recognition Paradigm in Rats. Frontiers in Pharmacology, 2017, 8, 709.	3.5	27
13	Progress in the development of histamine H <sub>3</sub> receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opinion on Therapeutic Patents, 2018, 28, 175-196.	5.0	27
14	Search for new multi-target compounds against Alzheimer's disease among histamine H3 receptor ligands. European Journal of Medicinal Chemistry, 2020, 185, 111785.	5.5	27
15	Aryl-1,3,5-triazine ligands of histamine H4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide. Inflammation Research, 2017, 66, 79-95.	4.0	26
16	Dualâ€Acting Diether Derivatives of Piperidine and Homopiperidine with Histamine H <sub>3</sub> Receptor Antagonistic and Anticholinesterase Activity. Archiv Der Pharmazie, 2012, 345, 591-597.	4.1	25
17	The Histamine H3 Receptor Antagonist DL77 Ameliorates MK801-Induced Memory Deficits in Rats. Frontiers in Neuroscience, 2018, 12, 42.	2.8	25
18	The Dual-Active Histamine H3 Receptor Antagonist and Acetylcholine Esterase Inhibitor E100 Alleviates Autistic-Like Behaviors and Oxidative Stress in Valproic Acid Induced Autism in Mice. International Journal of Molecular Sciences, 2020, 21, 3996.	4.1	25

Dorota Åażewska

#	Article	IF	CITATIONS
19	(2-Arylethenyl)-1,3,5-triazin-2-amines as a novel histamine H4 receptor ligands. European Journal of Medicinal Chemistry, 2015, 103, 238-251.	5.5	24
20	Novel naphthyloxy derivatives – Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry, 2018, 26, 2573-2585.	3.0	24
21	Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18. European Journal of Medicinal Chemistry, 2018, 155, 381-397.	5.5	22
22	Simultaneous Blockade of Histamine H3 Receptors and Inhibition of Acetylcholine Esterase Alleviate Autistic-Like Behaviors in BTBR T+ tf/J Mouse Model of Autism. Biomolecules, 2020, 10, 1251.	4.0	22
23	Antagonism of Histamine H3 receptors Alleviates Pentylenetetrazole-Induced Kindling and Associated Memory Deficits by Mitigating Oxidative Stress, Central Neurotransmitters, and c-Fos Protein Expression in Rats. Molecules, 2020, 25, 1575.	3.8	21
24	Cholinesterase inhibitory activity of chlorophenoxy derivatives—Histamine H3 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4140-4145.	2.2	20
25	lmidazo[2,1â€ <i>b</i> ]thiazoles, imidazo[2,1â€ <i>b</i> ]imidazoles and Pyrrolo[1,2â€ <i>c</i> ]imidazoles. synthesis, structure and evaluation of benzodiazepine receptor binding. Journal of Heterocyclic Chemistry, 2002, 39, 243-253.	2.6	19
26	Azines as histamine H4 receptor antagonists. Frontiers in Bioscience - Scholar, 2012, S4, 967-987.	2.1	19
27	The novel non-imidazole histamine H3 receptor antagonist DL77 reduces voluntary alcohol intake and ethanol-induced conditioned place preference in mice. Physiology and Behavior, 2015, 151, 189-197.	2.1	18
28	Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo. Molecules, 2018, 23, 2529.	3.8	18
29	Studies on Anticonvulsant Effects of Novel Histamine H3R Antagonists in Electrically and Chemically Induced Seizures in Rats. International Journal of Molecular Sciences, 2018, 19, 3386.	4.1	18
30	Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6. European Journal of Medicinal Chemistry, 2019, 178, 740-751.	5.5	18
31	Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro. Molecules, 2019, 24, 4472.	3.8	18
32	Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6682-6685.	2.2	17
33	Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 207, 112743.	5.5	17
34	Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H <sub>3</sub> and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties. ACS Chemical Neuroscience, 2022, 13, 1-15.	3.5	17
35	Piperidine variations in search for non-imidazole histamine H3 receptor ligands. Bioorganic and Medicinal Chemistry, 2008, 16, 8729-8736.	3.0	16
36	Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H3 receptor ligands. Bioorganic and Medicinal Chemistry, 2017, 25, 5341-5354.	3.0	16

#	Article	IF	CITATIONS
37	Role of Histamine H3 Receptor Antagonists on Intraocular Pressure Reduction in Rabbit Models of Transient Ocular Hypertension and Glaucoma. International Journal of Molecular Sciences, 2019, 20, 981.	4.1	16
38	Histamine H3 receptor antagonist E177 attenuates amnesia induced by dizocilpine without modulation of anxiety-like behaviors in rats. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 531-542.	2.2	14
39	Histamine H3R Antagonists: From Scaffold Hopping to Clinical Candidates. Receptors, 2016, , 109-155.	0.2	14
40	Cunninghamella as a Microbiological Model for Metabolism of Histamine H3 Receptor Antagonist 1-[3-(4-tert-Butylphenoxy)propyl]piperidine. Applied Biochemistry and Biotechnology, 2012, 168, 1584-1593.	2.9	13
41	Synthesis and biological activity of novel tert -amylphenoxyalkyl (homo)piperidine derivatives as histamine H 3 R ligands. Bioorganic and Medicinal Chemistry, 2017, 25, 2701-2712.	3.0	13
42	4-tert-Pentylphenoxyalkyl derivatives – Histamine H3 receptor ligands and monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3596-3600.	2.2	13
43	Synthesis and computer-aided analysis of the role of linker for novel ligands of the 5-HT6 serotonin receptor among substituted 1,3,5-triazinylpiperazines. Bioorganic Chemistry, 2019, 84, 319-325.	4.1	13
44	The Neuroprotective Effects of Histamine H3 Receptor Antagonist E177 on Pilocarpine-Induced Status Epilepticus in Rats. Molecules, 2019, 24, 4106.	3.8	12
45	Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands. Bioorganic and Medicinal Chemistry, 2009, 17, 3037-3042.	3.0	11
46	The lipophilicity estimation of 5-arylidene derivatives of (2-thio)hydantoin with antimycobacterial activity. Biomedical Chromatography, 2007, 21, 291-298.	1.7	10
47	The Synthesis of 1,3,5â€ŧriazine Derivatives and JNJ7777120 Analogues with Histamine H <sub>4</sub> Receptor Affinity and Their Interaction with <i>PTEN</i> Promoter. Chemical Biology and Drug Design, 2016, 88, 254-263.	3.2	10
48	Alkyl derivatives of 1,3,5-triazine as histamine H4 receptor ligands. Bioorganic and Medicinal Chemistry, 2019, 27, 1254-1262.	3.0	10
49	Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors. International Journal of Molecular Sciences, 2020, 21, 3411.	4.1	10
50	Chalcones as Potential Ligands for the Treatment of Parkinson's Disease. Pharmaceuticals, 2022, 15, 847.	3.8	9
51	Anticonvulsant evaluation of novel non-imidazole histamine H3R antagonists in different convulsion models in rats. Pharmacology Biochemistry and Behavior, 2018, 170, 14-24.	2.9	8
52	Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease. Bioorganic Chemistry, 2021, 114, 105129.	4.1	8
53	LC–MS–MS Method for the Analysis of New Non-Imidazole Histamine H3 Receptor Antagonist 1-[3-(4-tert-Butylphenoxy)propyl]piperidine in Rat Serum—Application to Pharmacokinetic Studies. Chromatographia, 2011, 73, 913-919.	1.3	6
54	Eosinophils adhesion assay as a tool for phenotypic drug screening - The pharmacology of 1,3,5 – Triazine and 1H-indole like derivatives against the human histamine H4 receptor. European Journal of Pharmacology, 2021, 890, 173611.	3.5	5

Dorota Åażewska

#	Article	IF	CITATIONS
55	Monocyclic and Fused Azines and Azoles as Histamine H4Receptor Ligands. Current Medicinal Chemistry, 2016, 23, 1870-1925.	2.4	5
56	The Search for Histamine H 4 Receptor Ligands with Anticancer Activity among Novel (Thio)urea Derivatives. ChemistrySelect, 2019, 4, 10943-10952.	1.5	4
57	Binding of 1-[3-(4-tert-butyl-phenoxy)propyl]piperidine, a new non imidazole histamine H3 receptor antagonist to bovine serum albumin. Acta Poloniae Pharmaceutica, 2012, 69, 1043-7.	0.1	4
58	Pharmacokinetics and tissue distribution of the new non-imidazole histamine H3 receptor antagonist 1-[3-(4-tert-butylphenoxy) propyl]piperidine in rats. Xenobiotica, 2015, 45, 912-920.	1.1	3
59	In silico and in vitro studies on interaction of novel non-imidazole histamine H3R antagonists with CYP3A4. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127147.	2.2	3
60	Biphenylalkoxyamine Derivatives–Histamine H3 Receptor Ligands with Butyrylcholinesterase Inhibitory Activity. Molecules, 2021, 26, 3580.	3.8	3
61	Ameliorating effects of histamine H3 receptor antagonist E177 on acute pentylenetetrazole-induced memory impairments in rats. Behavioural Brain Research, 2021, 405, 113193.	2.2	2
62	Search for histamine H4 receptor ligands in the group of 4-methylpiperazino amide derivatives. Inflammation Research, 2010, 59, 243-245.	4.0	1
63	Diether (substituted) piperidine derivatives as novel, histamine H3 receptor ligands. Inflammation Research, 2009, 58, 47-48.	4.0	0
64	Convenient way of synthesis and crystal structure of 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine, a histamine H4 receptor antagonist. Heterocyclic Communications, 2011, 17, .	1.2	0
65	Determination of in vitro metabolism of new non-imidazole histamine H3 receptor antagonist 1-[3-(4-tert-butylphenoxy)propyl]piperidine. Acta Poloniae Pharmaceutica, 2019, 76, 877-884.	0.1	0